To determine whether the cytotoxic response to VX-680 in SMARCA4-inactivated NSCLC lines was due to being generally vulnerable to any toxin, in parallel we screened our panel of NSCLC and HBEC lines with seven other drugs belonging to different classes of anticancer agents, as well as with a general chemical toxin (Supplementary Fig. 2a–h, Supplementary Data 3). This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.